CN Patent

CN108883111B — 有机化合物

Assigned to Intra Cellular Therapies Inc · Expires 2021-10-08 · 5y expired

What this patent protects

本发明涉及特定取代的杂环稠合γ‑咔啉，其前药，它们是本发明所述的游离、固体、药学上可接受的盐和/或基本上纯的形式，涉及它们的药物组合物，以及它们用于治疗涉及的5‑HT2A受体、5‑羟色胺转运蛋白(SERT)、关于多巴胺D1和D2受体信号系统的通路和/或μ‑阿片样受体的疾病的方法。

USPTO Abstract

本发明涉及特定取代的杂环稠合γ‑咔啉，其前药，它们是本发明所述的游离、固体、药学上可接受的盐和/或基本上纯的形式，涉及它们的药物组合物，以及它们用于治疗涉及的5‑HT2A受体、5‑羟色胺转运蛋白(SERT)、关于多巴胺D1和D2受体信号系统的通路和/或μ‑阿片样受体的疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108883111B
Jurisdiction
CN
Classification
—
Expires
2021-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.